≥2mg/ml

Cardiac Troponin I (cTnI) is synthesized in cardiac muscle and forms a structural complex with Troponin T and C. Its concentration in blood increases after the onset of chest pain and maintains peak for a couple of weeks. The cTnI protein is considered as useful diagnosis marker for acute myocardial infarction (AMI).

≥2mg/ml

Creatine kinase (CK) is a dimeric enzyme, including three isoforms of creatine kinase: BB, MM, and MB. Level of serum CK-MB will be increased within 4-6 hours after a myocardial infarction (MI). CK-MB is considered as a useful marker for the diagnosis of myocardial infarction.

S100 Antibody (2AC), mAb, Mouse

≥2mg/ml

S100 protein family contains variety of members such as ββ homodimer and αβ heterodimer. It is a useful marker for monitoring brain damage and detecting secondary neurological injuries. The concentration of S100 A8/A9 hetero complex increases in blood when special diseases take places, such as rheumatoid arthritis, cystic fibrosis, multiple scerlosis, and HIV infections. S100A8/A9 protein is a potential serum marker for diagnosis of pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).

LpPLA2 Antibody (10D46), mAb, Mouse

≥2mg/ml

Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme which participates in proinflammatory process. High concentration of LpPLA2 in serum indicates risk of heart attack and stroke. LpPLA2 is considered as specific coronary marker for diagnosing cardiovascular heart disease.

LpPLA2 Antibody (9C42), mAb, Mouse

≥2mg/ml

Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme which participates in proinflammatory process. High concentration of LpPLA2 in serum indicates risk of heart attack and stroke. LpPLA2 is considered as specific coronary marker for diagnosing cardiovascular heart disease.

≥2mg/ml

BNP and NT-proBNP are separated from precursor molecule proBNP via proteolytic processing. The BNP and NT-proBNP level in blood are proportional to the severity of cardiac dysfunction. They can be used for diagnosis of congestive heart failure (CHF).

≥2mg/ml

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

≥2mg/ml

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

FDP Antibody (6B6), mAb, Mouse

FDP Antibody (6B6), mAb, Mouse

Cardiac Troponin T (cTnT) Antibody (1H5C2), mAb, Mouse